Home
About Us
Core Team
Development History
Corporate Culture
S&T
Research Areas
Technology Platforms
Research and Development
Marketed Products
R&D Products
R&D Pipeline
Academic Progress
Blog
Company News
Media Reports
Join Us
Post-Doctoral Center
Contact Us
Major breakthrough in targeted therapy for pancreatic cancer: Data from the Phase III registration clinical study of nivolumab for pancreatic cancer will be unveiled soon!
View details
→
China's Pride! The Complete Collection of China-Developed Class 1 New Drugs Approved by ASCO in 2022!
[Case Share] Issue 157: Case Study on Nilotinib Treatment for Locally Advanced Nasopharyngeal Carcinoma
The 2022 ASCO Annual Meeting unveiled, for the first time, four groundbreaking research findings on nimotuzumab.
Biotech Pharma successfully completed the export delivery of monoclonal antibody bulk substance, overcoming challenges such as the pandemic.
[Case Share] Issue 156: Nivolumab Combined with Chemoradiotherapy for Hypopharyngeal Squamous Cell Carcinoma